NetWorth
LeaderPortfolio
Kirk
R
Rank #2039
UNITED STATES•Healthcare•Pharmaceuticals

Randal J. Kirk

Net Worth
$2.008B
+1.05% (24h)
Randal J. Kirk, a self-made billionaire, is a prominent figure in the pharmaceutical and biotechnology industries. His wealth source primarily stems from his investments in these sectors. His career includes founding and selling successful pharmaceutical companies, such as New River Pharmaceuticals, and his current role as the Executive Chairman of Third Security. Kirk, 72, is known for his strategic investments and innovative approaches to biotechnology, including his work in synthetic biology and genetic engineering. He is recognized for his contributions to the industry, and he holds a Doctor of Jurisprudence from the University of Virginia. As of March 2026, his net worth is estimated at $2.0 billion.

How to read Randal J. Kirk's profile

Public net-worth figures are estimates. They combine observable inputs—typically listed equity, disclosed transactions, and market prices—with editorial judgment where filings are incomplete (for example, private holdings, debt, or cross-holdings). For Randal J. Kirk, we anchor the narrative to Pharmaceuticals and Pharmaceuticals, then update the headline number as markets move. The chart on this page is meant to show trajectory, not a certified balance sheet.

When you see $2.008B alongside global rank #2039, interpret it as our best synthesis of widely cited ownership and price signals—not a claim about cash on hand. Estimates can diverge from other publishers because of different treatment of options, trusts, charitable vehicles, or illiquid assets. We document the general approach in methodology and welcome corrections via corrections.

Country (UNITED STATES) and career milestones on this page are curated for reader context; they should be verified against primary sources when used for research. Editorial metadata for this profile is refreshed on a rolling basis, with deeper audits at least annually (last noted cycle: 2026).

Looking for depth? When available, the dossier and timeline sections below add long-form context beyond the headline number—prioritize those modules when evaluating claims about strategy, controversies, or philanthropic commitments.

The Full Dossier

Early Life and Education

Randal J. Kirk was born in Pleasanton, California, on March 1, 1954. As the son of a U.S. Air Force master sergeant, his family relocated frequently, eventually settling in Virginia and Florida. Kirk's early life included an entrepreneurial spirit, demonstrated by selling greeting cards door-to-door at age nine with significant success. He earned a Bachelor of Arts in Economics from Radford University in 1976, followed by a Juris Doctor from the University of Virginia in 1979. He started his career as an attorney, practicing law in Bland, Virginia, from 1980 to 1990.

Rise to Success

In 1983, Kirk co-founded General Injectables and Vaccines, which he later sold. His most significant success came with New River Pharmaceuticals, which he founded in 1996 and took public in 2004. Kirk served as chairman and CEO and sold the company to Shire in 2007 for $2.6 billion, earning over $1 billion personally. In 1999, Kirk founded Third Security, LLC, a life sciences investment firm, where he currently serves as Senior Managing Director, CEO, and Chairman. From 2008 to 2020, he was the Chairman and CEO of Intrexon, a biotechnology company. In 2020, Intrexon adopted the name Precigen, and Kirk stepped down as CEO while remaining as Executive Chairman.

Key Business Strategies

Kirk's success is attributed to a focus on high-risk, high-reward investments and staying invested in companies until products reached the market. His strategy involved betting on a few small companies and staying the course. Kirk is known for his innovative approach to biotechnology, including genetic engineering and synthetic biology. His investments have made waves for innovative products, like apples that never brown and a genetically modified species of salmon.

Philanthropy

Kirk's philanthropy includes a $1 million donation to Radford University, which established the Zylphia Shu-En Kirk Endowment. He served on the boards of the Radford University Foundation and the University's Board of Visitors. Kirk has also donated to political causes and considers himself an independent. His philanthropy score is 1 on a scale of 1–5, indicating limited major charitable giving relative to his wealth.

Career Timeline

2020

Stepped down as CEO of Precigen

Remained as Executive Chairman.

2008

Chairman of Intrexon

Became chairman of Intrexon's board.

1999

Founded Third Security, LLC

Life sciences investment firm.

1996

Founded New River Pharmaceuticals

Served as chairman and CEO.

1983

Co-founded General Injectables and Vaccines

Founded the next-day pharmaceutical distributor.

1980

Admitted to the Bar

Became the only attorney in Bland, Virginia.

Philanthropic Impact

Education$1M

Zylphia Shu-En Kirk Endowment

Donation to Radford University.

Key Business Ventures & Holdings

CompanyStakeValue
Halozyme Therapeutics Inc—$0.894M
Precigen, Inc.4.60%$0.036M

Net Worth History

In-Depth Analysis

Early Life and Education

Randal J. Kirk was born in Pleasanton, California, on March 1, 1954. As the son of a U.S. Air Force master sergeant, his family relocated frequently, eventually settling in Virginia and Florida. Kirk's early life included an entrepreneurial spirit, demonstrated by selling greeting cards door-to-door at age nine with significant success. He earned a Bachelor of Arts in Economics from Radford University in 1976, followed by a Juris Doctor from the University of Virginia in 1979. He started his career as an attorney, practicing law in Bland, Virginia, from 1980 to 1990.

Rise to Success

In 1983, Kirk co-founded General Injectables and Vaccines, which he later sold. His most significant success came with New River Pharmaceuticals, which he founded in 1996 and took public in 2004. Kirk served as chairman and CEO and sold the company to Shire in 2007 for $2.6 billion, earning over $1 billion personally. In 1999, Kirk founded Third Security, LLC, a life sciences investment firm, where he currently serves as Senior Managing Director, CEO, and Chairman. From 2008 to 2020, he was the Chairman and CEO of Intrexon, a biotechnology company. In 2020, Intrexon adopted the name Precigen, and Kirk stepped down as CEO while remaining as Executive Chairman.

Key Business Strategies

Kirk's success is attributed to a focus on high-risk, high-reward investments and staying invested in companies until products reached the market. His strategy involved betting on a few small companies and staying the course. Kirk is known for his innovative approach to biotechnology, including genetic engineering and synthetic biology. His investments have made waves for innovative products, like apples that never brown and a genetically modified species of salmon.

Philanthropy

Kirk's philanthropy includes a $1 million donation to Radford University, which established the Zylphia Shu-En Kirk Endowment. He served on the boards of the Radford University Foundation and the University's Board of Visitors. Kirk has also donated to political causes and considers himself an independent. His philanthropy score is 1 on a scale of 1–5, indicating limited major charitable giving relative to his wealth.

Data Sources & Methodology

Figures for Randal J. Kirk are synthesized from the sources below and cross-checked against our net worth methodology. Estimates may lag market moves; see corrections to report discrepancies.

You may also like

HubAll BillionairesHubGlobal RankingsHubNewsroom